Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIBP Omicron Inactivated COVID-19 vaccine + WIBP Omicron Inactivated COVID-19 vaccine
- Development stage
- Unknown
- Lead developer
- China National Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
BIBP Omicron Inactivated COVID-19 vaccine + WIBP Omicron Inactivated COVID-19 vaccine is a combination regimen of two inactivated virus vaccines targeting the SARS-CoV-2 Omicron variant. Developed by the Beijing Institute of Biological Products (BIBP) and the Wuhan Institute of Biological Products (WIBP), both subsidiaries of the China National Pharmaceutical Group (Sinopharm), these vaccines utilize traditional inactivated virus technology. They are formulated specifically against the Omicron variant to provide broader protection compared to original-strain vaccines. The combination is primarily studied as a sequential or heterologous booster regimen in clinical trials, such as those conducted in Hong Kong, to evaluate safety and immunogenicity in individuals previously vaccinated with other COVID-19 vaccines.
- Brand names
- Sinopharm Omicron vaccine
- Other names
- Sinopharm Omicron Inactivated COVID-19 vaccineBIBP-OmicronWIBP-Omicron
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on BIBP Omicron Inactivated COVID-19 vaccine + WIBP Omicron Inactivated COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIBP Omicron Inactivated COVID-19 vaccine + WIBP Omicron Inactivated COVID-19 vaccine.